Communiqués PExA AB

Actions

PEXA B

SE0007412374

Equipement et technologie médicale avancés

Cours en clôture SPOTLIGHT STOCK MARKET AB 01/09/2026			Varia. 5j.	Varia. 1 janv.
0,3480 ^SEK	+5,78%		+5,78%	+59,63%

28/08	Pexa affiche des variations de résultats mineures : le PDG souligne qu'un nouvel apport de capital accroît nettement la marge de manœuvre	FW
28/08	PExA AB (publ) publie ses résultats pour le deuxième trimestre et le premier semestre clos le 30 juin 2026	CI

Communiqués

23/06	PExA : signs agreement with global pharmaceutical company for 10 instruments for clinical multicenter study in pulmonary fibrosis, with a value of approximately SEK 7.5 million	PU
10/06	PExA : U.S. government agency customer orders upgrade of existing PExA system	PU
02/06	PExA : New doctoral thesis strengthens PExA’s opportunities in lung cancer and other lung diseases	PU
13/05	PExA : partner in Dutch precision medicine project within COPD and interstitial lung diseases	PU
04/05	PExA : receives order from German Federal Institute BAuA for second instrument	PU
20/04	PExA : Additional funding strengthens a growing research environment in Örebro where PExA is used in multiple studies	PU
18/03	PExA : highlights the potential for early detection of lung diseases at Life Science Day – presentation now available online	PU
06/03	PExA : receives order from Norway’s national occupational health institute STAMI	PU
14/01	PExA : granted U.S. patent for sPOT technology developed to enhance analytical capabilities in exhaled breath	PU
09/01	PExA : lung cancer research instrument featured by Aftonbladet, Sweden’s largest news site	PU
18/12	PExA : Wallenberg Fellow Utilizes PExA’s Research Instrument in Groundbreaking Vaccine and Antibody Study for Respiratory Infections	PU
20/11	PExA : Research Instrument for Lung Cancer Detection Highlighted by Sweden’s Largest Radio News Programme	PU
14/11	PExA : SEK 27 million from the Swedish Cancer Society awarded to Sandra Lindstedt’s team in Lund for early detection of lung cancer	PU
31/10/25	PExA : awarded SEK 1 million from Vinnova for the next step toward lung-cancer diagnostics	PU
22/10/25	PExA : files patent application for biomarkers enabling early detection of lung cancer	PU
28/08/25	PExA : to Exhibit at the World’s Largest Lung Cancer Congress – WCLC 2025 in Barcelona	PU
27/08/25	PExA : signs its first rental and data-sharing agreement in Australia	PU
01/07/25	PExA : Karolinska Institute researchers launch pilot study using PExA technology to analyze antibody responses in the lower airways	PU
20/05/25	PExA : files patent to enable RNA fragmentomics in exhaled air— unlocking molecular insights from the small airways	PU
15/05/25	PExA : to showcase non-invasive lung research platform and present at Respiratory Innovation Summit during ATS 2025	PU
06/05/25	PExA : takes the next step — sharpening focus on clinical applications in lung diagnostics	PU
01/04/25	PExA : Aarhus University upgrades its PExA instrument – continued trust in groundbreaking lung research	PU
28/03/25	PExA : New research from Lund University may expand the donor lung pool for transplantation	PU
04/02/25	PExA : Rising lung cancer rates among non-smokers highlight the need for early detection	PU
15/01/25	PExA : New study highlights PExA’s potential as a novel method for non-invasive measurement of drug levels in the lung	PU